drugset / Trial / NCT02300935
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Phase 1
Withdrawn
SCRI Development Innovations, LLC
Celgene Corporation · collabGlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will investigate the combination of two drugs, trametinib and nab-paclitaxel, in patients with advanced unresectable or metastatic melanoma. Each drug has shown activity in trials of patients with melanoma. However, the combination of these two drugs has not been studied. In this trial the investigators will determine the maximum dose of the drug combination to be administered to patients with advanced unresectable or metastatic melanoma and examine the safety profile of the drug combination.
Timeline
- Start
- 2015-12
- Primary completion
- 2016-01-20
- Completion
- 2016-01-20
Outcome
Outcome not reported
Stopped: “Study concept was terminated.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | — | Intravenous |
| Subject | Trametinib | Small molecule | 1 mg | Oral |
| Subject | Trametinib | Small molecule | 1.5 mg | Oral |
| Subject | Trametinib | Small molecule | 2 mg | Oral |